Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma
Blood. 2023 Nov 2;142(18):1518-1528. doi: 10.1182/blood.2022019531.ABSTRACTFrom…
Quantifying the available capacity and resource needs for provision of CAR-T therapies in the National Health Service in Spain: a survey-based study
BMJ Open. 2023 Jul 25;13(7):e071371. doi: 10.1136/bmjopen-2022-071371.ABSTRACTOBJECTIVES:…
γ-Secretase inhibitors plus anti-BCMA chimeric antigen receptor T cells
Lancet Oncol. 2023 Jul;24(7):715-717. doi: 10.1016/S1470-2045(23)00283-8.NO…
Cellular therapy in lymphoma
Hematol Oncol. 2023 Jun 29. doi: 10.1002/hon.3200. Online ahead…
Immune effector cell-associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations
Blood. 2023 Sep 7;142(10):865-877. doi: 10.1182/blood.2023020578.ABSTRACTHematological…
Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma
N Engl J Med. 2023 Jul 13;389(2):148-157. doi: 10.1056/NEJMoa2301665.…
The activities and regulatory landscape of cellular therapies including hematopoietic cell transplantation in the world
Blood Cell Ther. 2022 Dec 23;5(Spec Edition):S15-S24. doi: 10.31547/bct-2022-013.…
Allogeneic hematopoietic stem cell transplantation for NK/T-cell lymphoma: an international collaborative analysis
Leukemia. 2023 Jul;37(7):1511-1520. doi: 10.1038/s41375-023-01924-x.…
Decrease of lethal infectious complications in the context of causes of death (COD) after hematopoietic cell transplantation: COD-2 and COD-1 study of the Infectious Diseases Working Party EBMT
Bone Marrow Transplant. 2023 Aug;58(8):881-892. doi: 10.1038/s41409-023-01998-2.…
An International Survey on Grading, Diagnosis, and Management of Immune Effector Cell-Associated Hematotoxicity (ICAHT) Following CAR T-cell Therapy on Behalf of the EBMT and EHA
Hemasphere. 2023 Apr 27;7(5):e889. doi: 10.1097/HS9.0000000000000889.…
Genetic variants of CTLA4 are associated with clinical outcome of patients with multiple myeloma
Front Immunol. 2023 Apr 12;14:1158105. doi: 10.3389/fimmu.2023.1158105.…
Randomized phase II study of weekly carfilzomib 70 mg/m2 and dexamethasone with or without cyclophosphamide in relapsed and/or refractory multiple myeloma patients
Haematologica. 2023 Oct 1;108(10):2753-2763. doi: 10.3324/haematol.2022.282490.ABSTRACTIn…
